Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9559797,MIC,"Trovafloxacin is a novel naphthyridone quinolone with promising activity against S. pneumoniae, including penicillin-resistant strains (MIC for 90% of the isolates tested, 0.25 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],0.25,6718,DB00685,Trovafloxacin
,9559797,MIC,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],0.03,6719,DB00685,Trovafloxacin
,9559797,MICs,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],4 to 8,6720,DB00685,Trovafloxacin
,9559797,MIC,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],32,6721,DB00685,Trovafloxacin
,22305082,retention times,The retention times of MBX and TVX were 4.9 and 6.6 min respectively.,Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305082/),min,4.9,7323,DB00685,Trovafloxacin
,22305082,retention times,The retention times of MBX and TVX were 4.9 and 6.6 min respectively.,Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305082/),min,6.6,7324,DB00685,Trovafloxacin
,22305082,detection,The detection and quantification limits for MBX and TVX were 2 ng/mL and 10 ng/mL respectively for both compounds.,Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305082/),[ng] / [ml],2,7325,DB00685,Trovafloxacin
,22305082,q,The detection and quantification limits for MBX and TVX were 2 ng/mL and 10 ng/mL respectively for both compounds.,Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305082/),[ng] / [ml],2,7326,DB00685,Trovafloxacin
,22305082,q,The detection and quantification limits for MBX and TVX were 2 ng/mL and 10 ng/mL respectively for both compounds.,Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305082/),[ng] / [ml],10,7327,DB00685,Trovafloxacin
,9222075,steady-state plasma concentrations,"For 7 days, the subjects received morning and evening theophylline doses adjusted to achieve steady-state plasma concentrations of 8-15 mg/L, the lower end of the therapeutic range.","Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222075/),[mg] / [l],8-15,15751,DB00685,Trovafloxacin
,9222075,Cmax,"On day 14, mean Cmax, AUC(0-12) and T(1/2) (measured on day 14 only) in group A were 10.15 mg/L, 107.32 mg x h/L and 9.0 h, respectively.","Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222075/),[mg] / [l],10.15,15752,DB00685,Trovafloxacin
,9222075,AUC(0-12),"On day 14, mean Cmax, AUC(0-12) and T(1/2) (measured on day 14 only) in group A were 10.15 mg/L, 107.32 mg x h/L and 9.0 h, respectively.","Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222075/),[h·mg] / [l],107.32,15753,DB00685,Trovafloxacin
,9222075,T(1/2),"On day 14, mean Cmax, AUC(0-12) and T(1/2) (measured on day 14 only) in group A were 10.15 mg/L, 107.32 mg x h/L and 9.0 h, respectively.","Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222075/),h,9.0,15754,DB00685,Trovafloxacin
,8737145,Cmax,"Following single doses, the mean Cmax values (mean +/- S.D.) were 1.0 +/- 0.3 and 2.9 +/- 0.4 mg/L for the 100 and 300 mg, respectively; those after 14-day consecutive daily dosing (day 17) were 1.1 +/- 0.2 and 3.3 +/- 0.5 mg/L, respectively.",Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),[mg] / [l],1.0,18177,DB00685,Trovafloxacin
,8737145,Cmax,"Following single doses, the mean Cmax values (mean +/- S.D.) were 1.0 +/- 0.3 and 2.9 +/- 0.4 mg/L for the 100 and 300 mg, respectively; those after 14-day consecutive daily dosing (day 17) were 1.1 +/- 0.2 and 3.3 +/- 0.5 mg/L, respectively.",Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),[mg] / [l],2.9,18178,DB00685,Trovafloxacin
,8737145,Cmax,"Following single doses, the mean Cmax values (mean +/- S.D.) were 1.0 +/- 0.3 and 2.9 +/- 0.4 mg/L for the 100 and 300 mg, respectively; those after 14-day consecutive daily dosing (day 17) were 1.1 +/- 0.2 and 3.3 +/- 0.5 mg/L, respectively.",Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),[mg] / [l],1.1,18179,DB00685,Trovafloxacin
,8737145,Cmax,"Following single doses, the mean Cmax values (mean +/- S.D.) were 1.0 +/- 0.3 and 2.9 +/- 0.4 mg/L for the 100 and 300 mg, respectively; those after 14-day consecutive daily dosing (day 17) were 1.1 +/- 0.2 and 3.3 +/- 0.5 mg/L, respectively.",Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),[mg] / [l],3.3,18180,DB00685,Trovafloxacin
,8737145,T1/2,"The mean values of T1/2 associated with the 100 and 300 mg doses were 9.2 +/- 1.2 on day 1 and 10.5 +/- 0.7 h on day 17; those after the 300 mg doses were 10.5 +/- 1.4 and 12.2 +/- 1.9 h, respectively.",Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),h,9.2,18181,DB00685,Trovafloxacin
,8737145,T1/2,"The mean values of T1/2 associated with the 100 and 300 mg doses were 9.2 +/- 1.2 on day 1 and 10.5 +/- 0.7 h on day 17; those after the 300 mg doses were 10.5 +/- 1.4 and 12.2 +/- 1.9 h, respectively.",Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),h,10.5,18182,DB00685,Trovafloxacin
,8737145,T1/2,"The mean values of T1/2 associated with the 100 and 300 mg doses were 9.2 +/- 1.2 on day 1 and 10.5 +/- 0.7 h on day 17; those after the 300 mg doses were 10.5 +/- 1.4 and 12.2 +/- 1.9 h, respectively.",Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),h,10.5,18183,DB00685,Trovafloxacin
,8737145,T1/2,"The mean values of T1/2 associated with the 100 and 300 mg doses were 9.2 +/- 1.2 on day 1 and 10.5 +/- 0.7 h on day 17; those after the 300 mg doses were 10.5 +/- 1.4 and 12.2 +/- 1.9 h, respectively.",Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),h,12.2,18184,DB00685,Trovafloxacin
,8737145,cumulative urinary recovery of,The cumulative urinary recovery of unchanged drug averaged 5.3% of the administered dose.,Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),%,5.3,18185,DB00685,Trovafloxacin
,8737145,renal clearance,Trovafloxacin renal clearance was 0.43 +/- 0.09 L/h.,Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),[l] / [h],0.43,18186,DB00685,Trovafloxacin
,8737145,free fraction,The free fraction of the drug in plasma was 23.8 +/- 6.1%.,Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737145/),%,23.8,18187,DB00685,Trovafloxacin
,9758286,maximum plasma trovafloxacin concentration,"Following a single 200 mg oral dose, the mean maximum plasma trovafloxacin concentration was 2.0+/-0.4 mg/l, the area under the concentration-time curve 22.0+/-5.5 mg x h/l and the elimination half-life 8.5 h.",Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758286/),[mg] / [l],2.0,24012,DB00685,Trovafloxacin
,9758286,area under the concentration-time curve,"Following a single 200 mg oral dose, the mean maximum plasma trovafloxacin concentration was 2.0+/-0.4 mg/l, the area under the concentration-time curve 22.0+/-5.5 mg x h/l and the elimination half-life 8.5 h.",Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758286/),[h·mg] / [l],22.0,24013,DB00685,Trovafloxacin
,9758286,elimination half-life,"Following a single 200 mg oral dose, the mean maximum plasma trovafloxacin concentration was 2.0+/-0.4 mg/l, the area under the concentration-time curve 22.0+/-5.5 mg x h/l and the elimination half-life 8.5 h.",Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758286/),h,8.5,24014,DB00685,Trovafloxacin
,9758286,bile : serum ratio,The mean bile : serum ratio of trovafloxacin was 14:9 and consistent with biliary elimination.,Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758286/),,14:9,24015,DB00685,Trovafloxacin
,9222076,Cmax,"After the oral dose of trovafloxacin, the mean Cmax and AUC were 2.2 mg/L and 30.4 mg x h/L, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[mg] / [l],2.2,25467,DB00685,Trovafloxacin
,9222076,AUC,"After the oral dose of trovafloxacin, the mean Cmax and AUC were 2.2 mg/L and 30.4 mg x h/L, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[h·mg] / [l],30.4,25468,DB00685,Trovafloxacin
,9222076,Cmax,"After the infusion of alatrofloxacin, the Cmax and AUC of trovafloxacin were 3.2 mg/L and 34.7 mg x h/L, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[mg] / [l],3.2,25469,DB00685,Trovafloxacin
,9222076,AUC,"After the infusion of alatrofloxacin, the Cmax and AUC of trovafloxacin were 3.2 mg/L and 34.7 mg x h/L, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[h·mg] / [l],34.7,25470,DB00685,Trovafloxacin
,9222076,T(1/2),The mean T(1/2) after both treatments was about 11 h.,Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),h,11,25471,DB00685,Trovafloxacin
,9222076,Cl,"The mean Cl and Vd(ss) of trovafloxacin after the infusion of alatrofloxacin were 1.32 mL/min/kg and 1.13 L/kg, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[ml] / [kg·min],1.32,25472,DB00685,Trovafloxacin
,9222076,Vd(ss),"The mean Cl and Vd(ss) of trovafloxacin after the infusion of alatrofloxacin were 1.32 mL/min/kg and 1.13 L/kg, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[l] / [kg],1.13,25473,DB00685,Trovafloxacin
,9222076,oral bioavailability,The mean oral bioavailability of trovafloxacin was estimated to be 87.6% (range 64.8-122.1%).,Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),%,87.6,25474,DB00685,Trovafloxacin
,9222076,Tmax,Mean Tmax after treatment B occurred 2.2 h later (3.6 h vs 1.4 h) than after treatment A.,Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),h,3.6,25475,DB00685,Trovafloxacin
,9222076,Tmax,Mean Tmax after treatment B occurred 2.2 h later (3.6 h vs 1.4 h) than after treatment A.,Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),h,1.4,25476,DB00685,Trovafloxacin
,9222076,Cmax,"Mean Cmax and AUC were 2.3 and 2.6 mg/L and 38.2 and 39.5 mg x h/L after B and A, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[mg] / [l],2.3,25477,DB00685,Trovafloxacin
,9222076,Cmax,"Mean Cmax and AUC were 2.3 and 2.6 mg/L and 38.2 and 39.5 mg x h/L after B and A, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[mg] / [l],2.6,25478,DB00685,Trovafloxacin
,9222076,AUC,"Mean Cmax and AUC were 2.3 and 2.6 mg/L and 38.2 and 39.5 mg x h/L after B and A, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[mg] / [l],2.6,25479,DB00685,Trovafloxacin
,9222076,AUC,"Mean Cmax and AUC were 2.3 and 2.6 mg/L and 38.2 and 39.5 mg x h/L after B and A, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[h·mg] / [l],38.2,25480,DB00685,Trovafloxacin
,9222076,AUC,"Mean Cmax and AUC were 2.3 and 2.6 mg/L and 38.2 and 39.5 mg x h/L after B and A, respectively.",Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),[h·mg] / [l],39.5,25481,DB00685,Trovafloxacin
,9222076,bioavailability,The mean bioavailability of trovafloxacin administered as treatment regimen B was 96.6% relative to that of treatment A.,Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),%,96.6,25482,DB00685,Trovafloxacin
,9222076,bioavailabilities,The respective mean bioavailabilities of trovafloxacin as treatments B and A were 91.3% and 94.5% respectively of that of treatment C.,Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),%,91.3,25483,DB00685,Trovafloxacin
,9222076,bioavailabilities,The respective mean bioavailabilities of trovafloxacin as treatments B and A were 91.3% and 94.5% respectively of that of treatment C.,Oral bioavailability of trovafloxacin with and without food in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222076/),%,94.5,25484,DB00685,Trovafloxacin
,8787877,maximum concentration,The mean maximum concentration observed in plasma was 2.9 micrograms/ml at a mean time of 0.75 h postdose.,"Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787877/),[μg] / [ml],2.9,33322,DB00685,Trovafloxacin
,8787877,mean time,The mean maximum concentration observed in plasma was 2.9 micrograms/ml at a mean time of 0.75 h postdose.,"Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787877/),h,0.75,33323,DB00685,Trovafloxacin
,8787877,maximum concentration,The mean maximum concentration observed in inflammatory fluid was 1.2 micrograms/ml at 4.0 h postdose.,"Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787877/),[μg] / [ml],1.2,33324,DB00685,Trovafloxacin
,8787877,elimination half-life,The mean elimination half-life in plasma was 7.8 h.,"Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787877/),h,7.8,33325,DB00685,Trovafloxacin
,8787877,overall penetration into inflammatory fluid,"The overall penetration into inflammatory fluid was 64%, as assessed by determining the ratio of the area under the concentration-time curves.","Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787877/),%,64,33326,DB00685,Trovafloxacin
,10404320,MIC,"Immunocompetent Balb/c mice were infected by intranasal inoculation of a cephalosporin-resistant S. pneumoniae isolate (MIC of ceftriaxone and trovafloxacin 2 and 0.06 mg/L, respectively).",Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404320/),[mg] / [l],2,70802,DB00685,Trovafloxacin
,10404320,MIC,"Immunocompetent Balb/c mice were infected by intranasal inoculation of a cephalosporin-resistant S. pneumoniae isolate (MIC of ceftriaxone and trovafloxacin 2 and 0.06 mg/L, respectively).",Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404320/),[mg] / [l],0.06,70803,DB00685,Trovafloxacin
,10404320,serum T1/2,The serum T1/2 was approximately 9 h and lung T1/2 varied from 5 to 9 h.,Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404320/),h,9,70804,DB00685,Trovafloxacin
,10404320,lung T1/2,The serum T1/2 was approximately 9 h and lung T1/2 varied from 5 to 9 h.,Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404320/),h,5 to 9,70805,DB00685,Trovafloxacin
,10404320,lung bacterial concentrations,"At the start of therapy lung bacterial concentrations were 8.4 +/- 0.3 log10 cfu/mL and 24 h later had decreased by 3.5 +/- 0.2, 4.0 +/- 0.2, 0.8 +/- 0.3 and 1.0 +/- 1.2 log10 cfu/mL with 30 mg/kg x 1, 10 mg/kg x 3, 10 mg/kg x 1 and 3.3 mg/kg x 3 regimens, respectively.",Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404320/),log10,8.4,70806,DB00685,Trovafloxacin
,10770751,peak trovafloxacin concentration,"There was rapid conversion of alatrofloxacin to trovafloxacin, with an average +/- standard deviation (SD) peak trovafloxacin concentration determined at the end of the infusion of 4.3 +/- 1.4 microg/ml.","Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770751/),[μg] / [ml],4.3,73815,DB00685,Trovafloxacin
,10770751,volume of distribution at steady state,"The primary pharmacokinetic parameters (average +/- SD) analyzed were volume of distribution at steady state (1.6 +/- 0.6 liters/kg), clearance (151 +/- 82 ml/h/kg), and half-life (9.8 +/- 2.9 h).","Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770751/),[l] / [kg],1.6,73816,DB00685,Trovafloxacin
,10770751,clearance,"The primary pharmacokinetic parameters (average +/- SD) analyzed were volume of distribution at steady state (1.6 +/- 0.6 liters/kg), clearance (151 +/- 82 ml/h/kg), and half-life (9.8 +/- 2.9 h).","Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770751/),[ml] / [h·kg],151,73817,DB00685,Trovafloxacin
,10770751,half-life,"The primary pharmacokinetic parameters (average +/- SD) analyzed were volume of distribution at steady state (1.6 +/- 0.6 liters/kg), clearance (151 +/- 82 ml/h/kg), and half-life (9.8 +/- 2.9 h).","Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770751/),h,9.8,73818,DB00685,Trovafloxacin
,10770751,area under the concentration-time curve,On the basis of the mean area under the concentration-time curve of 30.5 +/- 10.1 microg.,"Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770751/),μg,30.5,73819,DB00685,Trovafloxacin
,9727522,penetration ratio,"Following a single dose of trovafloxacin, maximal vitreous levels were achieved at 8 hours in infected eyes, with a penetration ratio of 36%.",Treatment of experimental Staphylococcus epidermidis endophthalmitis with oral trovafloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9727522/),%,36,77889,DB00685,Trovafloxacin
,9935253,bioavailability,"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91.3%, 109.5%) and Treatment D versus Treatment A (91.6%, 109.9%) were well within the bioequivalence criteria of 80% to 125%.",The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),%,91.3,87061,DB00685,Trovafloxacin
,9935253,bioavailability,"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91.3%, 109.5%) and Treatment D versus Treatment A (91.6%, 109.9%) were well within the bioequivalence criteria of 80% to 125%.",The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),%,109.5,87062,DB00685,Trovafloxacin
,9935253,bioavailability,"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91.3%, 109.5%) and Treatment D versus Treatment A (91.6%, 109.9%) were well within the bioequivalence criteria of 80% to 125%.",The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),%,91.6,87063,DB00685,Trovafloxacin
,9935253,bioavailability,"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91.3%, 109.5%) and Treatment D versus Treatment A (91.6%, 109.9%) were well within the bioequivalence criteria of 80% to 125%.",The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),%,109.9,87064,DB00685,Trovafloxacin
,9935253,area under the,"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91.3%, 109.5%) and Treatment D versus Treatment A (91.6%, 109.9%) were well within the bioequivalence criteria of 80% to 125%.",The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),%,91.3,87065,DB00685,Trovafloxacin
,9935253,area under the,"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91.3%, 109.5%) and Treatment D versus Treatment A (91.6%, 109.9%) were well within the bioequivalence criteria of 80% to 125%.",The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),%,109.5,87066,DB00685,Trovafloxacin
,9935253,area under the,"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91.3%, 109.5%) and Treatment D versus Treatment A (91.6%, 109.9%) were well within the bioequivalence criteria of 80% to 125%.",The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),%,91.6,87067,DB00685,Trovafloxacin
,9935253,area under the,"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91.3%, 109.5%) and Treatment D versus Treatment A (91.6%, 109.9%) were well within the bioequivalence criteria of 80% to 125%.",The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),%,109.9,87068,DB00685,Trovafloxacin
,9935253,Time to peak serum concentration (Tmax),Time to peak serum concentration (Tmax) was 1.7 hours after oral administration of trovafloxacin and 1.1 hours after administration directly into the stomach or duodenum through a nasogastric tube in the absence of concomitant enteral feeding.,The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),h,1.7,87069,DB00685,Trovafloxacin
,9935253,Time to peak serum concentration (Tmax),Time to peak serum concentration (Tmax) was 1.7 hours after oral administration of trovafloxacin and 1.1 hours after administration directly into the stomach or duodenum through a nasogastric tube in the absence of concomitant enteral feeding.,The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935253/),h,1.1,87070,DB00685,Trovafloxacin
,10582898,absolute bioavailability,The mean absolute bioavailability was 91%.,Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582898/),%,91,89449,DB00685,Trovafloxacin
,9222074,maximum plasma trovafloxacin concentrations,"Mean maximum plasma trovafloxacin concentrations for the four alatrofloxacin doses were 0.4, 1.8, 2.3 and 4.3 mg/L.","Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222074/),[mg] / [l],0.4,90442,DB00685,Trovafloxacin
,9222074,maximum plasma trovafloxacin concentrations,"Mean maximum plasma trovafloxacin concentrations for the four alatrofloxacin doses were 0.4, 1.8, 2.3 and 4.3 mg/L.","Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222074/),[mg] / [l],1.8,90443,DB00685,Trovafloxacin
,9222074,maximum plasma trovafloxacin concentrations,"Mean maximum plasma trovafloxacin concentrations for the four alatrofloxacin doses were 0.4, 1.8, 2.3 and 4.3 mg/L.","Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222074/),[mg] / [l],2.3,90444,DB00685,Trovafloxacin
,9222074,maximum plasma trovafloxacin concentrations,"Mean maximum plasma trovafloxacin concentrations for the four alatrofloxacin doses were 0.4, 1.8, 2.3 and 4.3 mg/L.","Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222074/),[mg] / [l],4.3,90445,DB00685,Trovafloxacin
,9222074,T(1/2)s,"The elimination half-life (T(1/2)) for trovafloxacin was independent of the dose and the mean T(1/2)s for the 100, 200 and 300 mg equivalent doses of alatrofloxacin were 10.4, 12.3 and 10.8 h.","Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222074/),h,10.4,90446,DB00685,Trovafloxacin
,9222074,T(1/2)s,"The elimination half-life (T(1/2)) for trovafloxacin was independent of the dose and the mean T(1/2)s for the 100, 200 and 300 mg equivalent doses of alatrofloxacin were 10.4, 12.3 and 10.8 h.","Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222074/),h,12.3,90447,DB00685,Trovafloxacin
,9222074,T(1/2)s,"The elimination half-life (T(1/2)) for trovafloxacin was independent of the dose and the mean T(1/2)s for the 100, 200 and 300 mg equivalent doses of alatrofloxacin were 10.4, 12.3 and 10.8 h.","Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222074/),h,10.8,90448,DB00685,Trovafloxacin
,9935250,elimination half-life,"Trovafloxacin, a new fluoronaphthyridone derivative related to fluoroquinolone antimicrobial drugs, has demonstrated the following characteristics: significant gram-positive and gram-negative activity; significant activity against anaerobes and atypical respiratory pathogens; approximately 11-hour elimination half-life, permitting once-daily administration; and good tissue penetration.",Pharmacokinetics and metabolism of single oral doses of trovafloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935250/),h,11,100494,DB00685,Trovafloxacin
,9935250,maximum concentrations,"In the second study, biliary trovafloxacin concentrations were highest between 1.5 and 10 hours postdose, and the maximum concentrations ranged from 18.9 to 37.9 microg/mL.",Pharmacokinetics and metabolism of single oral doses of trovafloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935250/),[μg] / [ml],18.9 to 37.9,100495,DB00685,Trovafloxacin
,9935250,bile:serum ratio,"The mean bile:serum ratio of trovafloxacin was 14.9, and the biliary concentration of parent drug was higher than that of its N-acetyl metabolite.",Pharmacokinetics and metabolism of single oral doses of trovafloxacin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935250/),,14.9,100496,DB00685,Trovafloxacin
,9935250,elimination half-life,"These pharmacokinetic and pharmacodynamic results, together with a broad antimicrobial spectrum, long 11-hour elimination half-life, and low drug-interaction potential, suggest that trovafloxacin may be particularly appropriate for use in the surgical setting.",Pharmacokinetics and metabolism of single oral doses of trovafloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935250/),h,11,100497,DB00685,Trovafloxacin
,8851571,systemic clearances,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[ml] / [kg·min],12.5,101548,DB00685,Trovafloxacin
,8851571,systemic clearances,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[ml] / [kg·min],11.1,101549,DB00685,Trovafloxacin
,8851571,systemic clearances,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[ml] / [kg·min],7.2,101550,DB00685,Trovafloxacin
,8851571,volumes of distribution,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[l] / [kg],0.9,101551,DB00685,Trovafloxacin
,8851571,volumes of distribution,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[l] / [kg],1.7,101552,DB00685,Trovafloxacin
,8851571,volumes of distribution,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[l] / [kg],4.3,101553,DB00685,Trovafloxacin
,8851571,elimination half-lives,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),h,0.7,101554,DB00685,Trovafloxacin
,8851571,elimination half-lives,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),h,1.8,101555,DB00685,Trovafloxacin
,8851571,elimination half-lives,"After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),h,7.0,101556,DB00685,Trovafloxacin
,8851571,maximum concentrations,"After the administration of oral doses of 50, 20, and 20 mg/kg to rats, dogs, and monkeys serum trovafloxacin concentrations reached a maximum at 0.6, 2.3, and 2.3 h, respectively, with respective maximum concentrations of trovafloxacin in serum of 11.5, 3.5, and 5.2 micrograms/ml; the corresponding elimination half-lives were 2.2, 2.5, and 7.5 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[μg] / [ml],11.5,101557,DB00685,Trovafloxacin
,8851571,maximum concentrations,"After the administration of oral doses of 50, 20, and 20 mg/kg to rats, dogs, and monkeys serum trovafloxacin concentrations reached a maximum at 0.6, 2.3, and 2.3 h, respectively, with respective maximum concentrations of trovafloxacin in serum of 11.5, 3.5, and 5.2 micrograms/ml; the corresponding elimination half-lives were 2.2, 2.5, and 7.5 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[μg] / [ml],3.5,101558,DB00685,Trovafloxacin
,8851571,maximum concentrations,"After the administration of oral doses of 50, 20, and 20 mg/kg to rats, dogs, and monkeys serum trovafloxacin concentrations reached a maximum at 0.6, 2.3, and 2.3 h, respectively, with respective maximum concentrations of trovafloxacin in serum of 11.5, 3.5, and 5.2 micrograms/ml; the corresponding elimination half-lives were 2.2, 2.5, and 7.5 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),[μg] / [ml],5.2,101559,DB00685,Trovafloxacin
,8851571,elimination half-lives,"After the administration of oral doses of 50, 20, and 20 mg/kg to rats, dogs, and monkeys serum trovafloxacin concentrations reached a maximum at 0.6, 2.3, and 2.3 h, respectively, with respective maximum concentrations of trovafloxacin in serum of 11.5, 3.5, and 5.2 micrograms/ml; the corresponding elimination half-lives were 2.2, 2.5, and 7.5 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),h,2.2,101560,DB00685,Trovafloxacin
,8851571,elimination half-lives,"After the administration of oral doses of 50, 20, and 20 mg/kg to rats, dogs, and monkeys serum trovafloxacin concentrations reached a maximum at 0.6, 2.3, and 2.3 h, respectively, with respective maximum concentrations of trovafloxacin in serum of 11.5, 3.5, and 5.2 micrograms/ml; the corresponding elimination half-lives were 2.2, 2.5, and 7.5 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),h,2.5,101561,DB00685,Trovafloxacin
,8851571,elimination half-lives,"After the administration of oral doses of 50, 20, and 20 mg/kg to rats, dogs, and monkeys serum trovafloxacin concentrations reached a maximum at 0.6, 2.3, and 2.3 h, respectively, with respective maximum concentrations of trovafloxacin in serum of 11.5, 3.5, and 5.2 micrograms/ml; the corresponding elimination half-lives were 2.2, 2.5, and 7.5 h.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),h,7.5,101562,DB00685,Trovafloxacin
,8851571,oral bioavailability,"The oral bioavailability of trovafloxacin was 68, 58, and 85% in rats, dogs, and monkeys, respectively.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),%,68,101563,DB00685,Trovafloxacin
,8851571,oral bioavailability,"The oral bioavailability of trovafloxacin was 68, 58, and 85% in rats, dogs, and monkeys, respectively.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),%,58,101564,DB00685,Trovafloxacin
,8851571,oral bioavailability,"The oral bioavailability of trovafloxacin was 68, 58, and 85% in rats, dogs, and monkeys, respectively.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),%,85,101565,DB00685,Trovafloxacin
,8851571,binding,"The binding of trovafloxacin to serum proteins was concentration independent, averaging 92, 75, and 66% for rats, dogs, and monkeys, respectively.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),%,92,101566,DB00685,Trovafloxacin
,8851571,binding,"The binding of trovafloxacin to serum proteins was concentration independent, averaging 92, 75, and 66% for rats, dogs, and monkeys, respectively.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),%,75,101567,DB00685,Trovafloxacin
,8851571,binding,"The binding of trovafloxacin to serum proteins was concentration independent, averaging 92, 75, and 66% for rats, dogs, and monkeys, respectively.","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),%,66,101568,DB00685,Trovafloxacin
less,8851571,urinary recoveries,"The urinary recoveries of unchanged drug were less than 5% in dogs and monkeys, with or without incubation with alkali or Glusulase (beta-glucuronidase and sulfatase).","Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851571/),%,5,101569,DB00685,Trovafloxacin
,11357519,peak concentration,HPLC analysis of the plasma concentrations in juvenile rats showed that the concentrations of trovafloxacin were considerably lower than those of the other fluoroquinolones that had been studied previously in our laboratory: the peak concentration of trovafloxacin was 14 +/- 2.9 mg/l (mean +/- SD) after a single dose of 600 mg/kg in juvenile rats.,Effects of fluoroquinolones on the locomotor activity in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11357519/),[mg] / [l],14,104393,DB00685,Trovafloxacin
,9107540,Cmax,"The Cmax of total radioactivity and unchanged trovafloxacin in serum was 3.2 micrograms-equiv/ml and 2.9 micrograms/ml, respectively, and peaked in 1.4 hr.",Excretion and metabolism of trovafloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107540/),[μgrams-equiv] / [ml],3.2,115128,DB00685,Trovafloxacin
,9107540,Cmax,"The Cmax of total radioactivity and unchanged trovafloxacin in serum was 3.2 micrograms-equiv/ml and 2.9 micrograms/ml, respectively, and peaked in 1.4 hr.",Excretion and metabolism of trovafloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107540/),[μg] / [ml],2.9,115129,DB00685,Trovafloxacin
,9107540,AUC0-infinity,"The mean AUC0-infinity for radioactivity and trovafloxacin was 58.2 micrograms-eq.hr/ml and 32.2 micrograms.hr/ml, respectively.",Excretion and metabolism of trovafloxacin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107540/),[h·μgrams-eq] / [ml],58.2,115130,DB00685,Trovafloxacin
,9107540,AUC0-infinity,"The mean AUC0-infinity for radioactivity and trovafloxacin was 58.2 micrograms-eq.hr/ml and 32.2 micrograms.hr/ml, respectively.",Excretion and metabolism of trovafloxacin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107540/),[h·μg] / [ml],32.2,115131,DB00685,Trovafloxacin
,10772370,half-life,"Calculated (mean +/- SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 +/- 1.8 hours, 161.3 +/- 41.1 ml/minute, and 1.4 +/- 0.4 L/kg.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),h,10.9,124267,DB00685,Trovafloxacin
,10772370,clearance at steady state,"Calculated (mean +/- SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 +/- 1.8 hours, 161.3 +/- 41.1 ml/minute, and 1.4 +/- 0.4 L/kg.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[ml] / [min],161.3,124268,DB00685,Trovafloxacin
,10772370,volume of distribution,"Calculated (mean +/- SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 +/- 1.8 hours, 161.3 +/- 41.1 ml/minute, and 1.4 +/- 0.4 L/kg.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[l] / [kg],1.4,124269,DB00685,Trovafloxacin
,10772370,maximum concentration,"In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 +/- 0.5 mg/L, 0.6 +/- 0.3 mg/L, and 34.2 +/- 10.6 mg x hr/L, respectively.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[mg] / [l],3.6,124270,DB00685,Trovafloxacin
,10772370,minimum concentration,"In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 +/- 0.5 mg/L, 0.6 +/- 0.3 mg/L, and 34.2 +/- 10.6 mg x hr/L, respectively.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[mg] / [l],0.6,124271,DB00685,Trovafloxacin
,10772370,area under the curve from 0-24 hours,"In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 +/- 0.5 mg/L, 0.6 +/- 0.3 mg/L, and 34.2 +/- 10.6 mg x hr/L, respectively.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[h·mg] / [l],34.2,124272,DB00685,Trovafloxacin
,8619569,50% protective doses,"In a model of murine pneumonia, trovafloxacin was more efficacious than temafloxacin, while ciprofloxacin failed against S. pneumoniae (50% protective doses, 2.1, 29.5, and >100 mg/kg, respectively).","In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619569/),[mg] / [kg],2.1,131231,DB00685,Trovafloxacin
,8619569,50% protective doses,"In a model of murine pneumonia, trovafloxacin was more efficacious than temafloxacin, while ciprofloxacin failed against S. pneumoniae (50% protective doses, 2.1, 29.5, and >100 mg/kg, respectively).","In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619569/),[mg] / [kg],29,131232,DB00685,Trovafloxacin
,8834872,peak serum,"Single-dose (10 mg of prodrug CP-116,517-27 per kg of body weight given intraperitoneally [i.p.], equivalent to 7.5 mg of trovafloxacin per kg) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak serum and lung trovafloxacin levels to be 3.8 micrograms/ml and 5.0 micrograms/g, respectively, at 0.5 h and 4.2 micrograms/ml and 2.9 micrograms/g, respectively, at 1 h.","Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8834872/),[μg] / [ml],3.8,135368,DB00685,Trovafloxacin
,8834872,lung trovafloxacin levels,"Single-dose (10 mg of prodrug CP-116,517-27 per kg of body weight given intraperitoneally [i.p.], equivalent to 7.5 mg of trovafloxacin per kg) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak serum and lung trovafloxacin levels to be 3.8 micrograms/ml and 5.0 micrograms/g, respectively, at 0.5 h and 4.2 micrograms/ml and 2.9 micrograms/g, respectively, at 1 h.","Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8834872/),[μg] / [g],5.0,135369,DB00685,Trovafloxacin
,8834872,lung trovafloxacin levels,"Single-dose (10 mg of prodrug CP-116,517-27 per kg of body weight given intraperitoneally [i.p.], equivalent to 7.5 mg of trovafloxacin per kg) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak serum and lung trovafloxacin levels to be 3.8 micrograms/ml and 5.0 micrograms/g, respectively, at 0.5 h and 4.2 micrograms/ml and 2.9 micrograms/g, respectively, at 1 h.","Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8834872/),[μg] / [ml],4.2,135370,DB00685,Trovafloxacin
,8834872,lung trovafloxacin levels,"Single-dose (10 mg of prodrug CP-116,517-27 per kg of body weight given intraperitoneally [i.p.], equivalent to 7.5 mg of trovafloxacin per kg) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak serum and lung trovafloxacin levels to be 3.8 micrograms/ml and 5.0 micrograms/g, respectively, at 0.5 h and 4.2 micrograms/ml and 2.9 micrograms/g, respectively, at 1 h.","Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8834872/),[μg] / [g],2.9,135371,DB00685,Trovafloxacin
,8834872,terminal half-lives of elimination,"The terminal half-lives of elimination from serum and lung were 0.8 and 1.1 h, respectively.","Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8834872/),h,0.8,135372,DB00685,Trovafloxacin
,8834872,terminal half-lives of elimination,"The terminal half-lives of elimination from serum and lung were 0.8 and 1.1 h, respectively.","Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8834872/),h,1.1,135373,DB00685,Trovafloxacin
,9517948,TRO half-life,"Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (microg x h/ml)/(microg/ml), respectively.",Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517948/),h,9.2,146776,DB00685,Trovafloxacin
,9517948,half-life,"Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (microg x h/ml)/(microg/ml), respectively.",Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517948/),h,4.0,146777,DB00685,Trovafloxacin
,9517948,area under the concentration-time curve (AUC)-to-MIC ratios,"Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (microg x h/ml)/(microg/ml), respectively.",Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517948/),[h·ml·μg] / [ml·μg],54 to 432,146778,DB00685,Trovafloxacin
,9517948,area under the concentration-time curve (AUC)-to-MIC ratios,"Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (microg x h/ml)/(microg/ml), respectively.",Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517948/),[h·ml·μg] / [ml·μg],59 to 473,146779,DB00685,Trovafloxacin
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,48.59,147172,DB00685,Trovafloxacin
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,49.9,147173,DB00685,Trovafloxacin
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,7.73,147174,DB00685,Trovafloxacin
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,6.6,147175,DB00685,Trovafloxacin
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.1,147176,DB00685,Trovafloxacin
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.6,147177,DB00685,Trovafloxacin
>,11864078,peak concentration,"Even though the concentration of trovafloxacin in infected muscle was reduced (p<0.01), the peak concentration was still >4 micro g/g and tissue levels remained above 2 micro g/g for more than 2 h.",Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864078/),[μg] / [g],4,156775,DB00685,Trovafloxacin
,11864078,peak,"Due to the lower concentrations that were achieved in the brain (peak approximately 5 micro g/g), it is expected that trovafloxacin will have limited central nervous system toxicity.",Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864078/),[μg] / [g],5,156776,DB00685,Trovafloxacin
,10223923,MICs,The MICs of ofloxacin and ciprofloxacin ranged from 1 to 2 micrograms/ml.,"Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),[μg] / [ml],1 to 2,171737,DB00685,Trovafloxacin
,10223923,MICs,"Trovafloxacin was 8- to 32-fold more potent, with MICs of 0.06 to 0.12 microgram/ml.","Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),[μg] / [ml],0.06 to 0.12,171738,DB00685,Trovafloxacin
,10223923,Times to 99.9% killing,Times to 99.9% killing were only 1 to 3 h.,"Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),h,1 to 3,171739,DB00685,Trovafloxacin
,10223923,area under the inhibitory curve/MIC ratio (AUC/MIC),"Although the rate of killing with ofloxacin was substantially slower than that with trovafloxacin, ofloxacin was also able to eradicate all eight strains from the model, despite a simulated area under the inhibitory curve/MIC ratio (AUC/MIC) of only 49.","Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),,49,171740,DB00685,Trovafloxacin
,10223923,AUC/MIC,"In contrast, ciprofloxacin eradicated only five strains (AUC/MIC = 44) from the model.","Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),,44,171741,DB00685,Trovafloxacin
,10223923,AUC/MIC,"Against the other three strains (AUC/MIC = 22), the antibacterial activity of ciprofloxacin was substantially diminished.","Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),,22,171742,DB00685,Trovafloxacin
,8522468,Cmax,"The corresponding mean Cmax values (mean +/- SD) were 0.3 +/- 0.0, 1.5 +/- 0.5, 4.4 +/- 1.1, 6.6 +/- 1.4 and 10.1 +/- 0.5 mg/L.","Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522468/),[mg] / [l],0.3,176086,DB00685,Trovafloxacin
,8522468,Cmax,"The corresponding mean Cmax values (mean +/- SD) were 0.3 +/- 0.0, 1.5 +/- 0.5, 4.4 +/- 1.1, 6.6 +/- 1.4 and 10.1 +/- 0.5 mg/L.","Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522468/),[mg] / [l],1.5,176087,DB00685,Trovafloxacin
,8522468,Cmax,"The corresponding mean Cmax values (mean +/- SD) were 0.3 +/- 0.0, 1.5 +/- 0.5, 4.4 +/- 1.1, 6.6 +/- 1.4 and 10.1 +/- 0.5 mg/L.","Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522468/),[mg] / [l],4.4,176088,DB00685,Trovafloxacin
,8522468,Cmax,"The corresponding mean Cmax values (mean +/- SD) were 0.3 +/- 0.0, 1.5 +/- 0.5, 4.4 +/- 1.1, 6.6 +/- 1.4 and 10.1 +/- 0.5 mg/L.","Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522468/),[mg] / [l],6.6,176089,DB00685,Trovafloxacin
,8522468,Cmax,"The corresponding mean Cmax values (mean +/- SD) were 0.3 +/- 0.0, 1.5 +/- 0.5, 4.4 +/- 1.1, 6.6 +/- 1.4 and 10.1 +/- 0.5 mg/L.","Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522468/),[mg] / [l],10.1,176090,DB00685,Trovafloxacin
,8522468,Terminal-phase half-life,"Terminal-phase half-life was independent of dose, with an overall mean of 9.9 +/- 2.5 h.","Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522468/),h,9.9,176091,DB00685,Trovafloxacin
,8522468,renal clearance,"Over the dosing range, trovafloxacin renal clearance was fairly constant, averaging 0.67 +/- 0.36 L/h.","Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522468/),[l] / [h],0.67,176092,DB00685,Trovafloxacin
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.6,176468,DB00685,Trovafloxacin
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.7,176469,DB00685,Trovafloxacin
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.2,176470,DB00685,Trovafloxacin
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.0,176471,DB00685,Trovafloxacin
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,1.8,176472,DB00685,Trovafloxacin
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,4.3,176473,DB00685,Trovafloxacin
at,10424513,peak plasma concentration/MIC ratio,"When the peak concentrations for both agents were compared to standard twofold dilution minimum inhibitory concentration (MIC) values for pneumococcal isolates, it was discovered that the breakpoint MIC value at which each compound would no longer achieve a peak plasma concentration/MIC ratio of at least 12:1 was 0.5 mg/L for levofloxacin and 0.25 mg/L for alatrofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],12:1,177798,DB00685,Trovafloxacin
,10424513,peak plasma concentration/MIC ratio,"When the peak concentrations for both agents were compared to standard twofold dilution minimum inhibitory concentration (MIC) values for pneumococcal isolates, it was discovered that the breakpoint MIC value at which each compound would no longer achieve a peak plasma concentration/MIC ratio of at least 12:1 was 0.5 mg/L for levofloxacin and 0.25 mg/L for alatrofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],0.5,177799,DB00685,Trovafloxacin
,10424513,peak plasma concentration/MIC ratio,"When the peak concentrations for both agents were compared to standard twofold dilution minimum inhibitory concentration (MIC) values for pneumococcal isolates, it was discovered that the breakpoint MIC value at which each compound would no longer achieve a peak plasma concentration/MIC ratio of at least 12:1 was 0.5 mg/L for levofloxacin and 0.25 mg/L for alatrofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],0.25,177800,DB00685,Trovafloxacin
,10424513,MIC,"Based on the MIC that inhibits 90% of isolates of Streptococcus pneumoniae for both of these agents (1.0 to 2.0 mg/L for levofloxacin and 0.125 to 0.25 mg/L for trovafloxacin), our results indicate that although the once-daily regimen of alatrofloxacin appears to be appropriate for this pathogen, a more aggressive regimen may need to be investigated to optimize the clinical and microbiological effects of levofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],1.0 to 2.0,177801,DB00685,Trovafloxacin
,10424513,MIC,"Based on the MIC that inhibits 90% of isolates of Streptococcus pneumoniae for both of these agents (1.0 to 2.0 mg/L for levofloxacin and 0.125 to 0.25 mg/L for trovafloxacin), our results indicate that although the once-daily regimen of alatrofloxacin appears to be appropriate for this pathogen, a more aggressive regimen may need to be investigated to optimize the clinical and microbiological effects of levofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],0.125 to 0.25,177802,DB00685,Trovafloxacin
,9089427,Cmax,"There was no significant difference between the geometric mean values for Cmax of theophylline, 6.42 micrograms/mL and 6.00 micrograms mL on days 1 and 8, respectively.","Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089427/),[μg] / [ml],6.42,186684,DB00685,Trovafloxacin
,9089427,Cmax,"There was no significant difference between the geometric mean values for Cmax of theophylline, 6.42 micrograms/mL and 6.00 micrograms mL on days 1 and 8, respectively.","Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089427/),ml·μg,6.00,186685,DB00685,Trovafloxacin
,9797213,AUC/MICs,"The AMEs of TR and CI against gram-negative bacteria with similar susceptibilities to both drugs were related to AUC/MICs that varied over similar eight-fold ranges [from 54 to 432 and from 59 to 473 (microg . h/ml)/(microg/ml), respectively].",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[h·ml·μg] / [ml·μg],54 to 432,187562,DB00685,Trovafloxacin
,9797213,AUC/MICs,"The AMEs of TR and CI against gram-negative bacteria with similar susceptibilities to both drugs were related to AUC/MICs that varied over similar eight-fold ranges [from 54 to 432 and from 59 to 473 (microg . h/ml)/(microg/ml), respectively].",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[h·ml·μg] / [ml·μg],59 to 473,187563,DB00685,Trovafloxacin
,9797213,half-lives,"In each experiment monoexponential pharmacokinetic profiles of TR and CI were simulated with half-lives of 9.2 and 4.0 h, respectively.",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),h,9.2,187564,DB00685,Trovafloxacin
,9797213,half-lives,"In each experiment monoexponential pharmacokinetic profiles of TR and CI were simulated with half-lives of 9.2 and 4.0 h, respectively.",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),h,4.0,187565,DB00685,Trovafloxacin
,9797213,MIC,"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[μg] / [ml],0.25,187566,DB00685,Trovafloxacin
,9797213,MIC of CI [MICCI],"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[μg] / [ml],0.12,187567,DB00685,Trovafloxacin
,9797213,MICTR,"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[μg] / [ml],0.3,187568,DB00685,Trovafloxacin
,9797213,MICCI,"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),,0,187569,DB00685,Trovafloxacin
,9797213,MICTR,"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),μ,0.25,187570,DB00685,Trovafloxacin
,9797213,AUC/MIC breakpoint,"The predicted value of the AUC/MIC breakpoint for TR [mean for all three bacteria, 63 (microg . h/ml)/(microg/ml)] was approximately twofold lower than that for CI.",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[h·ml·μg] / [ml·μg],63,187571,DB00685,Trovafloxacin
,9449263,MICs,"Trovafloxacin MICs ranged from 0.5 to 32 mg/liter, and the nine strains of vancomycin-resistant E. faecium for which MICs were < or =2 mg/liter were more likely to show a reduction of 2 log units or more in viable counts in time-kill assays than were strains for which MICs were higher.",Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449263/),[mg] / [l],0.5 to 32,188550,DB00685,Trovafloxacin
<,9449263,MICs,"Trovafloxacin MICs ranged from 0.5 to 32 mg/liter, and the nine strains of vancomycin-resistant E. faecium for which MICs were < or =2 mg/liter were more likely to show a reduction of 2 log units or more in viable counts in time-kill assays than were strains for which MICs were higher.",Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449263/),[mg] / [l],2,188551,DB00685,Trovafloxacin
,9449263,MIC,"Synergism with ampicillin-sulbactam was found for only one strain (trovafloxacin MIC, 16 mg/liter).",Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449263/),[mg] / [l],16,188552,DB00685,Trovafloxacin
< or =,9449263,MICs,These data suggest that this high dose of trovafloxacin (with or without ampicillin-sulbactam) might be useful against strains of vancomycin-resistant E. faecium for which MICs were < or =2 mg/liter.,Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449263/),[mg] / [l],2,188553,DB00685,Trovafloxacin
,9222077,area under the curve (AUC),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],14.2,190917,DB00685,Trovafloxacin
,9222077,area under the curve (AUC),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],30.2,190918,DB00685,Trovafloxacin
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,8.3,190919,DB00685,Trovafloxacin
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,8.5,190920,DB00685,Trovafloxacin
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],42.1,190921,DB00685,Trovafloxacin
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,12.4,190922,DB00685,Trovafloxacin
,9222077,Kel-corrected relative bioavailabilities,"The mean Kel-corrected relative bioavailabilities for A and C were 50% and 104%, respectively, suggesting a large reduction in the initial absorption of trovafloxacin with A.",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,50,190923,DB00685,Trovafloxacin
,9222077,Kel-corrected relative bioavailabilities,"The mean Kel-corrected relative bioavailabilities for A and C were 50% and 104%, respectively, suggesting a large reduction in the initial absorption of trovafloxacin with A.",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,104,190924,DB00685,Trovafloxacin
,9222077,relative bioavailability,The mean relative bioavailability after D was 82%.,Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,82,190925,DB00685,Trovafloxacin
,9758288,maximum observed serum trovafloxacin concentration,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[μg] / [ml],2.4,210599,DB00685,Trovafloxacin
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[h·μg] / [ml],27.8,210600,DB00685,Trovafloxacin
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),h,1.4,210601,DB00685,Trovafloxacin
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[μg] / [ml],2.5,210602,DB00685,Trovafloxacin
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[h·μg] / [ml],27.1,210603,DB00685,Trovafloxacin
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),h,1.5,210604,DB00685,Trovafloxacin
,9758288,earliest,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[h·μg] / [ml],27.8,210605,DB00685,Trovafloxacin
,9758288,earliest,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[h·μg] / [ml],27.1,210606,DB00685,Trovafloxacin
,9758288,time to the maximum serum concentration,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),h,1.5,210607,DB00685,Trovafloxacin
,10382890,CSF,"Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after Infusion mean CSF concentrations were 0.59+/-0.18, 0.74+/-0.14, 1.12+/-0.12 and 1.07+/-0.35 mg/L, respectively.",Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382890/),[mg] / [l],0.59,210999,DB00685,Trovafloxacin
,10382890,CSF,"Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after Infusion mean CSF concentrations were 0.59+/-0.18, 0.74+/-0.14, 1.12+/-0.12 and 1.07+/-0.35 mg/L, respectively.",Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382890/),[mg] / [l],0.74,211000,DB00685,Trovafloxacin
,10382890,CSF,"Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after Infusion mean CSF concentrations were 0.59+/-0.18, 0.74+/-0.14, 1.12+/-0.12 and 1.07+/-0.35 mg/L, respectively.",Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382890/),[mg] / [l],1.12,211001,DB00685,Trovafloxacin
,10382890,CSF,"Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after Infusion mean CSF concentrations were 0.59+/-0.18, 0.74+/-0.14, 1.12+/-0.12 and 1.07+/-0.35 mg/L, respectively.",Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382890/),[mg] / [l],1.07,211002,DB00685,Trovafloxacin
,10382890,concentrations,"Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after Infusion mean CSF concentrations were 0.59+/-0.18, 0.74+/-0.14, 1.12+/-0.12 and 1.07+/-0.35 mg/L, respectively.",Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382890/),[mg] / [l],0.59,211003,DB00685,Trovafloxacin
,10382890,concentrations,"Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after Infusion mean CSF concentrations were 0.59+/-0.18, 0.74+/-0.14, 1.12+/-0.12 and 1.07+/-0.35 mg/L, respectively.",Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382890/),[mg] / [l],0.74,211004,DB00685,Trovafloxacin
,10382890,concentrations,"Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after Infusion mean CSF concentrations were 0.59+/-0.18, 0.74+/-0.14, 1.12+/-0.12 and 1.07+/-0.35 mg/L, respectively.",Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382890/),[mg] / [l],1.12,211005,DB00685,Trovafloxacin
,10382890,concentrations,"Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after Infusion mean CSF concentrations were 0.59+/-0.18, 0.74+/-0.14, 1.12+/-0.12 and 1.07+/-0.35 mg/L, respectively.",Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382890/),[mg] / [l],1.07,211006,DB00685,Trovafloxacin
,14982762,maximum concentration of drug in serum (C(max),"The pulmonary pharmacokinetic parameters in mice infected with strain P-4241 and treated with garenoxacin or TVA (25 mg/kg of body weight) were as follows: maximum concentration of drug in serum (C(max); 17.3 and 21.2 micro g/ml, respectively), C(max)/MIC ratio (288 and 170, respectively), area under the concentration-time curve (AUC; 48.5 and 250 microg.",Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982762/),[μg] / [ml],17.3,227777,DB00685,Trovafloxacin
,14982762,maximum concentration of drug in serum (C(max),"The pulmonary pharmacokinetic parameters in mice infected with strain P-4241 and treated with garenoxacin or TVA (25 mg/kg of body weight) were as follows: maximum concentration of drug in serum (C(max); 17.3 and 21.2 micro g/ml, respectively), C(max)/MIC ratio (288 and 170, respectively), area under the concentration-time curve (AUC; 48.5 and 250 microg.",Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982762/),[μg] / [ml],21.2,227778,DB00685,Trovafloxacin
,14982762,C(max)/MIC ratio,"The pulmonary pharmacokinetic parameters in mice infected with strain P-4241 and treated with garenoxacin or TVA (25 mg/kg of body weight) were as follows: maximum concentration of drug in serum (C(max); 17.3 and 21.2 micro g/ml, respectively), C(max)/MIC ratio (288 and 170, respectively), area under the concentration-time curve (AUC; 48.5 and 250 microg.",Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982762/),,288,227779,DB00685,Trovafloxacin
,14982762,C(max)/MIC ratio,"The pulmonary pharmacokinetic parameters in mice infected with strain P-4241 and treated with garenoxacin or TVA (25 mg/kg of body weight) were as follows: maximum concentration of drug in serum (C(max); 17.3 and 21.2 micro g/ml, respectively), C(max)/MIC ratio (288 and 170, respectively), area under the concentration-time curve (AUC; 48.5 and 250 microg.",Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982762/),,170,227780,DB00685,Trovafloxacin
,14982762,area under the concentration-time curve (AUC,"The pulmonary pharmacokinetic parameters in mice infected with strain P-4241 and treated with garenoxacin or TVA (25 mg/kg of body weight) were as follows: maximum concentration of drug in serum (C(max); 17.3 and 21.2 micro g/ml, respectively), C(max)/MIC ratio (288 and 170, respectively), area under the concentration-time curve (AUC; 48.5 and 250 microg.",Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982762/),μg,48.5,227781,DB00685,Trovafloxacin
,14982762,area under the concentration-time curve (AUC,"The pulmonary pharmacokinetic parameters in mice infected with strain P-4241 and treated with garenoxacin or TVA (25 mg/kg of body weight) were as follows: maximum concentration of drug in serum (C(max); 17.3 and 21.2 micro g/ml, respectively), C(max)/MIC ratio (288 and 170, respectively), area under the concentration-time curve (AUC; 48.5 and 250 microg.",Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982762/),μg,250,227782,DB00685,Trovafloxacin
,14982762,AUC/MIC ratio,"h/ml, respectively), and AUC/MIC ratio (808 and 2000, respectively).",Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982762/),,808,227783,DB00685,Trovafloxacin
,14982762,AUC/MIC ratio,"h/ml, respectively), and AUC/MIC ratio (808 and 2000, respectively).",Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982762/),,2000,227784,DB00685,Trovafloxacin
,10049257,half-lives,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),h,9.2,230600,DB00685,Trovafloxacin
,10049257,half-lives,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),h,4,230601,DB00685,Trovafloxacin
,10049257,ratios of area under the concentration-time curve (AUC) to MIC,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),[h·μg] / [milliliter]],58 to 466,230602,DB00685,Trovafloxacin
,10049257,ratios of area under the concentration-time curve (AUC) to MIC,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),[h·μg] / [milliliter]],116 to 932,230603,DB00685,Trovafloxacin
,10049257,ratios of area under the concentration-time curve (AUC) to MIC,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),[h·μg] / [milliliter]],58,230604,DB00685,Trovafloxacin
,10049257,ratios of area under the concentration-time curve (AUC) to MIC,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),[h·μg] / [milliliter]],116,230605,DB00685,Trovafloxacin
,10049257,c/b ratios,"Since the c/b ratios for trovafloxacin and ciprofloxacin against E. coli were much lower (0.3 to 0.4) than that for ampicillin-sulbactam as examined previously (1.9), the inoculum effect with the quinolones may be much less pronounced than with the beta-lactams.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),,0.3 to 0.4,230606,DB00685,Trovafloxacin
,10049257,c/b ratios,"Since the c/b ratios for trovafloxacin and ciprofloxacin against E. coli were much lower (0.3 to 0.4) than that for ampicillin-sulbactam as examined previously (1.9), the inoculum effect with the quinolones may be much less pronounced than with the beta-lactams.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),,1,230607,DB00685,Trovafloxacin
,9687405,peak concentrations,"Particularly high peak concentrations (micrograms per gram; mean +/- standard error of the mean [SEM]) were achieved in the liver (35.06 +/- 5.89), pancreas (32.36 +/- 20. 18), kidney (27.20 +/- 10.68), lung (22.51 +/- 7.11), and spleen (21. 77 +/- 11.33).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [gram],35.06,235851,DB00685,Trovafloxacin
,9687405,peak concentrations,"Particularly high peak concentrations (micrograms per gram; mean +/- standard error of the mean [SEM]) were achieved in the liver (35.06 +/- 5.89), pancreas (32.36 +/- 20. 18), kidney (27.20 +/- 10.68), lung (22.51 +/- 7.11), and spleen (21. 77 +/- 11.33).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [gram],32.36,235852,DB00685,Trovafloxacin
,9687405,peak concentrations,"Particularly high peak concentrations (micrograms per gram; mean +/- standard error of the mean [SEM]) were achieved in the liver (35.06 +/- 5.89), pancreas (32.36 +/- 20. 18), kidney (27.20 +/- 10.68), lung (22.51 +/- 7.11), and spleen (21. 77 +/- 11.33).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [gram],27.20,235853,DB00685,Trovafloxacin
,9687405,peak concentrations,"Particularly high peak concentrations (micrograms per gram; mean +/- standard error of the mean [SEM]) were achieved in the liver (35.06 +/- 5.89), pancreas (32.36 +/- 20. 18), kidney (27.20 +/- 10.68), lung (22.51 +/- 7.11), and spleen (21. 77 +/- 11.33).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [gram],22.51,235854,DB00685,Trovafloxacin
,9687405,peak concentrations,"Particularly high peak concentrations (micrograms per gram; mean +/- standard error of the mean [SEM]) were achieved in the liver (35.06 +/- 5.89), pancreas (32.36 +/- 20. 18), kidney (27.20 +/- 10.68), lung (22.51 +/- 7.11), and spleen (21. 77 +/- 11.33).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [gram],21. 77,235855,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,3.25,235856,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,7.23,235857,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,11.29,235858,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,9.50,235859,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,4.74,235860,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,1.32,235861,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,4.42,235862,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,1.51,235863,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,2.46,235864,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,4.94,235865,DB00685,Trovafloxacin
,9687405,Plateau concentrations,"Plateau concentrations (measured at 2 to 8 h; micrograms per gram; mean +/- SEM) were 3.25 +/- 0.43 in the myocardium, 7.23 +/- 0.95 in the lung, 11.29 +/- 0.75 in the liver, 9.50 +/- 2.72 in the pancreas, 4.74 +/- 0.54 in the spleen, 1.32 +/- 0.09 in the bowel, 4.42 +/- 0.32 in the kidney, 1.51 +/- 0.15 in the bone, 2.46 +/- 0.17 in the muscle, 4.94 +/- 1.17 in the prostate, and 3.27 +/- 0.49 in the uterus.",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),,3.27,235866,DB00685,Trovafloxacin
,9687405,peak,"In the brain, the concentrations (peak, approximately 2.63 +/- 1.49 microg/g; plateau, approximately 0.91 +/- 0.15 microg/g) exceeded the MIC90s for such common causes of central nervous system infections as Streptococcus pneumoniae (MIC90, <0.2 microg/ml), Neisseria meningitidis (MIC90, <0.008 microg/ml), and Haemophilus influenzae (MIC90, <0.03 microg/ml).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [g],2.63,235867,DB00685,Trovafloxacin
<,9687405,MIC90,"In the brain, the concentrations (peak, approximately 2.63 +/- 1.49 microg/g; plateau, approximately 0.91 +/- 0.15 microg/g) exceeded the MIC90s for such common causes of central nervous system infections as Streptococcus pneumoniae (MIC90, <0.2 microg/ml), Neisseria meningitidis (MIC90, <0.008 microg/ml), and Haemophilus influenzae (MIC90, <0.03 microg/ml).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [ml],0.2,235868,DB00685,Trovafloxacin
<,9687405,MIC90,"In the brain, the concentrations (peak, approximately 2.63 +/- 1.49 microg/g; plateau, approximately 0.91 +/- 0.15 microg/g) exceeded the MIC90s for such common causes of central nervous system infections as Streptococcus pneumoniae (MIC90, <0.2 microg/ml), Neisseria meningitidis (MIC90, <0.008 microg/ml), and Haemophilus influenzae (MIC90, <0.03 microg/ml).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [ml],0.008,235869,DB00685,Trovafloxacin
<,9687405,MIC90,"In the brain, the concentrations (peak, approximately 2.63 +/- 1.49 microg/g; plateau, approximately 0.91 +/- 0.15 microg/g) exceeded the MIC90s for such common causes of central nervous system infections as Streptococcus pneumoniae (MIC90, <0.2 microg/ml), Neisseria meningitidis (MIC90, <0.008 microg/ml), and Haemophilus influenzae (MIC90, <0.03 microg/ml).",Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687405/),[μg] / [ml],0.03,235870,DB00685,Trovafloxacin
,11673035,MIC,The serum bactericidal activity against 2 Streptococcus pneumoniae strains (ciprofloxacin MIC 1 and 4 mg/l) was measured in 12 volunteers who received oral single doses of gemifloxacin 320 mg and trovafloxacin 200 mg in a crossover fashion.,Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],1,249355,DB00685,Trovafloxacin
,11673035,MIC,The serum bactericidal activity against 2 Streptococcus pneumoniae strains (ciprofloxacin MIC 1 and 4 mg/l) was measured in 12 volunteers who received oral single doses of gemifloxacin 320 mg and trovafloxacin 200 mg in a crossover fashion.,Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],4,249356,DB00685,Trovafloxacin
,11673035,MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],0.015,249357,DB00685,Trovafloxacin
,11673035,MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],0.03,249358,DB00685,Trovafloxacin
,11673035,C(max)/MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,104,249359,DB00685,Trovafloxacin
,11673035,C(max)/MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,52,249360,DB00685,Trovafloxacin
,11673035,AUC(0-24 h)/MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,532,249361,DB00685,Trovafloxacin
,11673035,AUC(0-24 h)/MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,266,249362,DB00685,Trovafloxacin
,11673035,area under the bactericidal curve (AUBC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,168,249363,DB00685,Trovafloxacin
,11673035,area under the bactericidal curve (AUBC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,30,249364,DB00685,Trovafloxacin
,11673035,MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],0.25,249365,DB00685,Trovafloxacin
,11673035,MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],0.06,249366,DB00685,Trovafloxacin
,11673035,C(max)/MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,8.6,249367,DB00685,Trovafloxacin
,11673035,C(max)/MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,36,249368,DB00685,Trovafloxacin
,11673035,AUC(0-24 h)/MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,85,249369,DB00685,Trovafloxacin
,11673035,AUC(0-24 h)/MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,356,249370,DB00685,Trovafloxacin
,11673035,AUBCs,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,2,249371,DB00685,Trovafloxacin
,11673035,AUBCs,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,22,249372,DB00685,Trovafloxacin
,27517552,maximum plasma concentration,"The mean maximum plasma concentration, area under the concentration-time curve, and elimination half-life of trovafloxacin were 3.6 mg/L, 37.4 mg/L·h, and 12.1h, respectively.",Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27517552/),[mg] / [l],3.6,251023,DB00685,Trovafloxacin
,27517552,area under the concentration-time curve,"The mean maximum plasma concentration, area under the concentration-time curve, and elimination half-life of trovafloxacin were 3.6 mg/L, 37.4 mg/L·h, and 12.1h, respectively.",Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27517552/),[mg] / [h·l],37.4,251024,DB00685,Trovafloxacin
,27517552,elimination half-life,"The mean maximum plasma concentration, area under the concentration-time curve, and elimination half-life of trovafloxacin were 3.6 mg/L, 37.4 mg/L·h, and 12.1h, respectively.",Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27517552/),h,12.1,251025,DB00685,Trovafloxacin
,27517552,tissue concentrations,"The mean tissue concentrations at the subcutaneous and deep adipose sites were 0.43 and 0.41 μ/g, respectively.",Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27517552/),[μ] / [g],0.43,251026,DB00685,Trovafloxacin
,27517552,tissue concentrations,"The mean tissue concentrations at the subcutaneous and deep adipose sites were 0.43 and 0.41 μ/g, respectively.",Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27517552/),[μ] / [g],0.41,251027,DB00685,Trovafloxacin
under,10436550,renal excretion,The renal excretion is under 8%; it doesn't require any doses adjustment in renal insufficiency.,[Pharmacokinetics of trovafloxacin: its clinical significance]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10436550/),%,8,260080,DB00685,Trovafloxacin
,9758287,clearance,Trovafloxacin clearance (82-85 ml x h/kg) and volume of distribution (1.3-1.6 l/kg) were independent of dose.,"Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758287/),[h·ml] / [kg],82-85,261481,DB00685,Trovafloxacin
,9758287,volume of distribution,Trovafloxacin clearance (82-85 ml x h/kg) and volume of distribution (1.3-1.6 l/kg) were independent of dose.,"Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758287/),[l] / [kg],1.3-1.6,261482,DB00685,Trovafloxacin
,9758287,maximum serum concentration,"A plot of the weight-adjusted dose of trovafloxacin in individual subjects against the maximum serum concentration following single and multiple dosing, indicated that the maximum serum concentration increased 1 microg/ml for each 1 mg/kg of trovafloxacin administered.","Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758287/),[μg] / [ml],1,261483,DB00685,Trovafloxacin
,9935251,maximum colonic tissue concentration,The maximum colonic tissue concentration was 2.8 microg/g in a sample taken 2 hours after dosing.,Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935251/),[μg] / [g],2.8,261942,DB00685,Trovafloxacin
,9935251,Colonic tissue/serum concentration ratios,Colonic tissue/serum concentration ratios in samples taken 2-10 hours after the end of infusion ranged from 0.8 to 1.47.,Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935251/),,0.8,261943,DB00685,Trovafloxacin
,9935251,Colonic tissue/serum concentration ratios,Colonic tissue/serum concentration ratios in samples taken 2-10 hours after the end of infusion ranged from 0.8 to 1.47.,Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9935251/),,1,261944,DB00685,Trovafloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],6.21,273557,DB00685,Trovafloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],4.34,273558,DB00685,Trovafloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],3.42,273559,DB00685,Trovafloxacin
,10991830,Elimination half-lives,Elimination half-lives ranged from 12.12+/-3.93 h (grepafloxacin) to 5.37+/-0.82 h (ciprofloxacin).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),h,12.12,273560,DB00685,Trovafloxacin
,10991830,Elimination half-lives,Elimination half-lives ranged from 12.12+/-3.93 h (grepafloxacin) to 5.37+/-0.82 h (ciprofloxacin).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),h,5.37,273561,DB00685,Trovafloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],44.8,273562,DB00685,Trovafloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],39.3,273563,DB00685,Trovafloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],30,273564,DB00685,Trovafloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],5.75,273565,DB00685,Trovafloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.48,273566,DB00685,Trovafloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.17,273567,DB00685,Trovafloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.09,273568,DB00685,Trovafloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],19.7,273569,DB00685,Trovafloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],19.5,273570,DB00685,Trovafloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],4.6,273571,DB00685,Trovafloxacin
